Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias

Brain

Volumn 127, Issue 5, 2004, Pages 1075-1084

  Calon, Frédéric ^a   Dridi, Mehdi ^a   Hornykiewicz, Oleh ^b,c   Bédard, Paul J ^a   Rajput, Ali H ^b   Di Paolo, Thérèse ^a,d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Adenosine A2A receptors; Motor complications; Parkinson's disease; Putamen; SCH 58261

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; CATECHOLAMINE; LEVODOPA; MESSENGER RNA; DOPAMINE;

AUTOPSY; AUTORADIOGRAPHY; BINDING SITE; BRAIN LEVEL; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DENERVATION; DOPAMINERGIC SYSTEM; DRUG RESPONSE; DRUG TARGETING; DYSKINESIA; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LONG TERM CARE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PUTAMEN; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; STRIATONIGRAL DEGENERATION; AGED; ARTICLE; CASE CONTROL STUDY; COMPUTER ASSISTED DIAGNOSIS; METABOLISM; METHODOLOGY;

AGED; AUTORADIOGRAPHY; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; DOPAMINE; DYSKINESIAS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; LEVODOPA; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A;

EID: 2442595210     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh128     Document Type: Review

References (81)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.
3. Andersson M, Konradi C, Cenci MA. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 2001; 21: 9930-43.
4. Aoyama S, Koga K, Mori A, Miyaji H, Sekine S, Kase H, et al. Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res 2002; 953: 119-25.
5. Aubert I, Ghorayeb I, Normand E, Bloch B. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol 2000; 418: 22-32.
6. Bai G, Kusiak JW. Cloning and analysis of the 5′ flanking sequence of the rat N-methyl-D-aspartate receptor 1 (NMDAR1) gene. Biochim Biophys Acta 1993; 1152: 197-200.
7. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61: 293-6.
8. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, et al. A(2A) antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003; 184: 285-94.
9. Blanchet PJ, Boucher R, Bedard PJ. Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian Brain Res 1994; 650: 32-9.
10. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-93.
11. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999; 290: 1034-40.
12. Bove J, Marin C, Bonastre M, Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 2002; 46: 251-7.
13. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998; 13: 871-6.
14. Brotchie JM. CB(I) cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003; 3: 54-61.
15. Calon F, Di Paolo T. Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 2002; 8: 449-54.
16. Calon F, Tahar AH, Blanchet PJ, Morissette M, Grondin R, Goulet M, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 2000; 23 (10 Suppl): S92-100.
17. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002; 61: 186-96.
18. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003; 18: 241-53.
19. Carta AR, Pinna A, Cauli O, Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 2002; 44: 166-74.
20. Cenci MA. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 2002; 23: 105-9.
21. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001; 98: 1970-5.
22. Chu YY, Tu KH, Lee YC, Kuo ZJ, Lai HL, Chern Y. Characterization of the rat A2a adenosine receptor gene. DNA Cell Biol 1996; 15: 329-37.
23. Cole RL, Konradi C, Douglass J, Hyman SE. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 1995; 14: 813-23.
24. Crossman AR. Functional anatomy of movement disorders. J Anat 2000; 196: 519-25.
25. Cunha RA, Johansson B, Constantino MD, Sebastiao AM, Fredholm BB. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 261-71.
26. Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm BB. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol 1997; 121: 353-60.
27. Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 1996; 8: 365-81.
28. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47 (4 Suppl 1): S2-9.
29. Ferre S, Popoli P, Gimenez-Llort L, Rimondini R, Muller CE, Stromberg I, et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001; 7: 235-41.
30. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002; 22: 1054-62.
31. Fredholm BB, Lindstrom K, Dionisotti S, Ongini E. [3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 1998; 70: 1210-6.
32. Furlong TJ, Pierce KD, Selbie LA, Shine J. Molecular characterization of a human brain adenosine A2 receptor. Brain Res Mol Brain Res 1992; 15: 62-6.
33. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999; 52: 1673-7.
34. Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001; 171: 139-46.
35. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091-7.
36. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
37. Hurley MJ, Mash DC, Jenner P. Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett 2000; 291: 54-8.
38. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000; 47 (4 Suppl 1): S90-9.
39. Kaelin-Lang A, Liniger P, Probst A, Lauterburg T, Burgunder JM. Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J Neural Transm 2000; 107: 851-9.
40. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507-13.
41. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321-7.
42. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001; 65: 1447-57.
43. Kemp JM, Powell TP. The cortico-striate projection in the monkey. Brain 1970; 93: 525-46.
44. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995; 28: 311-8.
45. Klein M, Pieri I, Uhlmann F, Pfizenmaier K, Eisel U. Cloning and characterization of promoter and 5′-UTR of the NMDA receptor subunit epsilon 2: evidence for alternative splicing of 5′-non-coding exon. Gene 1998; 208: 259-69.
46. Kostic VS, Svetel M, Sternic N, Dragasevic N, Przedborski S. Theophylline increases 'on' time in advanced parkinsonian patients. Neurology 1999; 52: 1916.
47. Kulisevsky J, Barbanoj M, Gironell A, Antonijoan R, Casas M, Pascual-Sedano B. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease. Clin Neuropharmacol 2002; 25: 25-31.
48. Lee YC, Chang CW, Su CW, Lin TN, Sun SH, Lai HL, et al. The 5′ untranslated regions of the rat A2A adenosine receptor gene function as negative translational regulators. J Neurochem 1999; 73: 1790-8.
49. Lindstrom K, Ongini E, Fredholm BB. The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 539-41.
50. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of 1-DOPA-induced dyskinesia. J Neurochem 2003; 84: 1398-410.
51. Mally J, Stone TW. The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 1994; 46: 515-7.
52. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson disease. Neurology 1981; 31: 125-31.
53. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991; 42: 697-706.
54. Miyawaki E, Lyons K, Pahwa R, Troster AI, Hubble J, Smith D, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997; 20: 523-30.
55. Morelli M, Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 2001; 22: 71-2.
56. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res 1997; 49: 55-62.
57. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000a; 23 (10 Suppl): S2-7.
58. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000b; 47 (4 Suppl 1): S22-32.
59. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci 1990; 13: 254-8.
60. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995; 20: 91-127.
61. Peterfreund RA, MacCollin M, Gusella J, Fink JS. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem 1996; 66: 362-8.
62. Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001; 39: 233-8.
63. Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 2002; 446: 75-82.
64. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984; 12: 1687-96.
65. Quik M, Police S, Langston JW, Di Monte DA. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 2002; 113: 213-20.
66. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002; 17: 289-96.
67. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001; 24: 313-23.
68. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-91.
69. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997; 18: 338-44.
70. Schiffmann SN, Vanderhaeghen JJ. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 1993; 13: 1080-7.
71. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991; 130: 177-81.
72. Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, et al. Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 1995; 21: 364-72.
73. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997; 27: 322-35.
74. Svenningsson P, Le Moine C, Aubert I, Burbaud P, Fredholm BB, Bloch B. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 1998; 399: 229-40.
75. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999; 59: 355-96.
76. Tekumalla PK, Calon F, Rahman Z, Birdi S, Rajput AH, Hornykiewicz O, et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 2001; 50: 813-6.
77. Vallone D, Pellecchia MT, Morelli M, Verde P, DiChiara G, Barone P. Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. Brain Res Mol Brain Res 1997; 52: 307-17.
78. Weisinger G. The transcriptional regulation of the preproenkephalin gene. Biochem J 1995; 307: 617-29.
79. Yelnik J, Damier P, Bejjani BP, Francois C, Gervais D, Dormont D, et al. Functional mapping of the human globus pallidus: contrasting effect of stimulation in the internal and external pallidum in Parkinson's disease. Neuroscience 2000; 101: 77-87.
80. Yoshida S, Nambu A, Jinnai K. The distribution of the globus pallidus neurons with input from various cortical areas in the monkeys. Brain Res 1993; 611: 170-4.
81. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 2000; 12: 1096-104.